Search
Ripretinib
go.drugbank.com/drugs/DB14840ApprovedInvestigationalRipretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020. … [L13769] It is the first drug approved as a fourth-line therapy in the specific setting of prior treatment with a minimum of 3 other kinase inhibitors.[L13778]
Dezocine
go.drugbank.com/drugs/DB01209ApprovedInvestigationalDezocine is a very effective alternative to fentanyl when administered during outpatient laparoscopy, although is associated with an increased incidence of postoperative nausea.
Zoliflodacin
go.drugbank.com/drugs/DB12817ApprovedInvestigationalFDA in December 2025, following Fast Track, Qualified Infectious Disease Product, and Priority Review designations.[L54743,L54803] … [A275268] Zoliflodacin is a first-in-class spiropyrimidinetrione antibiotic designed to address this need by inhibiting bacterial type II topoisomerases (DNA gyrase and topoisomerase IV), thereby blocking
Viltolarsen
go.drugbank.com/drugs/DB15005ApprovedInvestigational[A218176] Viltolarsen was granted accelerated FDA approval on August 12, 2020, based on data showing an increase in dystrophin levels in skeletal muscle of patients treated with viltolarsen; this approval … Viltolarsen is a phosphorodiamidate morpholino oligonucleotide (PMO); PMOs are oligonucleotides in which the five-membered ribofuranosyl ring is replaced with a six-membered morpholino ring, and the phosphodiester
Tetrachlorodecaoxide
go.drugbank.com/drugs/DB05389ApprovedThe Corporation has commenced a Phase II clinical trial in an effort to demonstrate the efficacy of WF10 in combination with Xeloda (capecitabine) in the treatment of pancreatic cancer. … Certain preclinical evidence and clinical pilot data suggest that WF10 may be effective in treating certain cancers.
Categories: Compounds used in a research, industrial, or household settingBezitramide
go.drugbank.com/drugs/DB01459ApprovedIllicitWithdrawnAfter cases of fatal overdose in the Netherlands in 2004 the drug was withdrawn from the market. Bezitramide has never been FDA approved and is currently a schedule II drug. … Bezitramide is a narcotic analgesic which was discovered in 1961, clinically tested around the 1970's [A14383], and marketed under the name Burgodin.
Calcium carbimide
go.drugbank.com/drugs/DB09116ApprovedWithdrawn[A31516] This drug was developed by Lederle Cyanamid Canada Inc and approved for marketing in Canada in 1959. The current status of calcium carbimide is cancelled post marketing.[L1113] … Its effects are similar to the drug disulfiram (Antabuse) in that it interferes with the normal metabolism of alcohol by preventing the breakdown of the metabolic product acetaldehyde.
Categories: Drugs Used in Addictive Disorders, Drugs Used in Alcohol DependenceUCB7362
go.drugbank.com/drugs/DB17096ExperimentalIt has shown high potency in biochemical (IC<sub>50</sub> = 7 nM), _in vitro_ (_P. falciparum_ 3D7 lactate dehydrogenase growth inhibition assay IC<sub>50</sub> = 10 nM), and _in vivo_ (50 mg/kg dose … in mice) studies.
Nedosiran
go.drugbank.com/drugs/DB17635ApprovedInvestigational[A261685] Nedosiran was approved by the FDA on October 2<sup>nd</sup>, 2023, under the brand name RIVFLOZA to lower urinary oxalate levels in children 9 years of age and older and adults with primary … Nedosiran is an RNA interference targeting hepatic lactate dehydrogenase, the enzyme responsible for the conversion of glyoxylate to oxalate.
Rimegepant
go.drugbank.com/drugs/DB12457ApprovedInvestigational[L11028] It received FDA approval on February 27, 2020 for the acute treatment migraine headache,[L11974] and was subsequently approved by the European Commission in April 2022 for both the treatment and … safer for use in patients with contraindications to standard therapy.